about
ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines.Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.Fibronectin attachment protein from bacillus Calmette-Guerin as targeting agent for bladder tumor cells.Improving Compliance With a Single Post-Operative Dose of Intravesical Chemotherapy After Transurethral Resection of Bladder Tumour.Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant.
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Bladder cancer: current optimal intravesical treatment.
@ast
Bladder cancer: current optimal intravesical treatment.
@en
type
label
Bladder cancer: current optimal intravesical treatment.
@ast
Bladder cancer: current optimal intravesical treatment.
@en
prefLabel
Bladder cancer: current optimal intravesical treatment.
@ast
Bladder cancer: current optimal intravesical treatment.
@en
P2093
P1433
P1476
Bladder cancer: current optimal intravesical treatment
@en
P2093
Donald L Lamm
William R McGee
P304
323-6, 331-2
P577
2005-10-01T00:00:00Z